Early Sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: A preliminary study

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Boudou Rouquette, Pascaline ^a,b,c   Narjoz, Céline ^c,d   Golmard, Jean Louis ^e   Thomas Schoemann, Audrey ^a,b,f   Mir, Olivier ^a,b,c   Taieb, Fabrice ^b   Durand, Jean Philippe ^a,b   Coriat, Romain ^a,b,c   Dauphin, Alain ^b   Vidal, Michel ^b,f   Tod, Michel ^g,h   Loriot, Marie Anne ^c,d   Goldwasser, François ^a,b,c   Blanchet, Benoit ^a,b  

^a Centre d'Étude et de Recours aux Inhibiteurs de l'Angiogénèse   (France)

^b Unité de Cancérologie médicale ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f CNRS   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A9; MULTIDRUG RESISTANCE PROTEIN 1; SORAFENIB;

ABCB1 GENE; ABCG2 GENE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CYP3A5 GENE; DIARRHEA; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; PHARMACOGENETICS; RISK ASSESSMENT; SEX DIFFERENCE; SOLID TUMOR; URIDINE DIPHOSPHATE GLUCURONYLTRANSFERASE 1A9 GENE;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DIARRHEA; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SKIN;

EID: 84865053668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042875     Document Type: Article

References (40)

1. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
2. Iyer R, Fetterly G, Lugade A, Thanavala Y, (2011) Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 11: 1943-1955.
3. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, et al. (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9: 275-287.
4. Porta C, Paglino C, Imarisio I, Bonomi L, (2007) Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7: 127-134.
5. van Erp NP, Gelderblom H, Guchelaar HJ, (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35: 692-706.
6. European Medicines Agency Website. Available: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000690/WC500027707.pdf. Accessed 2012 February 4.
7. Tod M, Mir O, Bancelin N, Coriat R, Thomas-Schoemann A, et al. (2011) Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 28: 3199-3207.
8. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, et al. (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72: 294-305.
9. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972.
10. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y, (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78: 351-361.
11. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C, (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307: 117-128.
12. Agarwal S, Sane R, Ohlfest JR, Elmquist WF, (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336: 223-233.
13. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, et al. (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 9: 319-326.
14. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, et al. (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27: 4406-4412.
15. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, et al. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26: 1119-1127.
16. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, et al. (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6: 432-438.
17. Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, et al. (2011) Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 12: 159-170.
18. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98: 1739-1742.
19. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, Del Alba AG, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
20. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, et al. (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80: 136-145.
21. Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, et al. (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45: 2316-2323.
22. White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, et al. (2011) Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 17: 4862-4871.
23. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, et al. (2011) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66: 357-371.
24. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0.
25. National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v4.0.
26. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, et al. (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49: 1109-1114.
27. Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, et al. (2011) Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs: Oct 18 [Epub ahead of print].
28. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772.
29. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, et al. (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44: 1051-1065.
30. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, et al. (2011) Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 41: 296-302.
31. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15: 1411-1416.
32. Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, et al. (2012) Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Annals of Oncology: January 6 [Epub ahead of print].
33. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437.
34. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, et al. (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67: 93-101.
35. Mathijssen RH, Sparreboom A (2009) Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 85: 23; author reply 24.
36. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006.
37. Gnoth MJ, Sandmann S, Engel K, Radtke M, (2010) In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 38: 1341-1346.
38. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, et al. (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12: 6073-6078.
39. Treinen-Moslen M, Kanz MF, (2006) Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road. Pharmacol Ther 112: 649-667.
40. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, et al. (2011) Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs 29: 1511-1514.